Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.

Oncotarget - 20 Dec 2016

Mukherjee Nabanita, Almeida Adam, Partyka Katie A, Lu Yan, Schwan Josianna V, Lambert Karoline, Rogers Madison, Robinson William A, Robinson Steven E, Applegate Allison J, Amato Carol M, Luo Yuchun, Fujita Mayumi, Norris David A, Shellman Yiqun G

Abstract excerpt

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent relapse. Here we examined whether combining a GSI (γ-Secretase Inhibitor) with ABT-737 (a small molecule...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Precursor Protein Secretases
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Self Renewal

Share to Drug Synergism

Share to Neurofibromin 1

Share to Nitrophenols

Share to Oligopeptides

Share to Proto-Oncogene Proteins c-bcl-2

Source

Open in PubMed Open full text

Identifiers

PMID: 27829238
DOI: 10.18632/oncotarget.13141
PMCID: PMC5356684

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.PMID 27829238Read ↗

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.Semantic proximity Read ↗

p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.Semantic proximity Read ↗

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapySemantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.Semantic proximity Read ↗

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeSemantic proximity Read ↗

TGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosisSemantic proximity Read ↗

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapiesSemantic proximity Read ↗

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.Semantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.Semantic proximity Read ↗

Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.